CD4+T lymphocytes were infected with HIV-1 at a MOI of 0.01 using ViroMag.
This paper shows the efficiency of ViroMag from
OZ Biosciences to enhance infection and transduction in primary CD4+ T lymphocytes even with a very low MOI.
article reference: J Immunol Methods. 2013 Dec 25. pii: S0022-1759(13)00370-0.
Measuring inhibition of HIV replication by ex vivo CD8+ T cells.
AbstractHIV replication is unrestrained in
vivo
in the vast majority of infected subjects, and the ability of some rare
individuals to control this virus is poorly understood. Standard
immunogenicity assays for detecting
HIV-1-specific
CD8+ T-cell responses, such as IFN-γ ELISpot and intracellular cytokine staining, generally fail to correlate with in
vivo inhibition of
HIV replication. Several viral
inhibition assays, which measure the effectiveness of
CD8+ T-cell responses in suppressing
HIV replication in vitro, have been described; but most depend on in vitro expansion of
CD8+ T cells, and some show inhibitory activity in
HIV-negative individuals. We have optimized an assay to assess the suppressive capability of
CD8+ T cells directly
ex vivo,
eliminating the potential for altering their function through
activation or expansion prior to assay setup, and thereby enhancing the
assay's sensitivity by avoiding non-specific
inhibition. With this method, the ability of
ex vivo CD8+ T cells to control
HIV-1
replication
in vitro can be quantified over several orders of magnitude.
Specifically, our assay can be used to better define the antiviral
function of
CD8+ T cells induced by vaccination, and can provide insight into their ability to control viral
replication if
HIV infection occurs post-vaccination.
ViroMag from OZ Biosciences is a magnetic nanoparticles formulation optimized for increasing any kind of virus infection and transduction both in vitro and in vivo.
No comments:
Post a Comment